Diametrically Patterned Dural Graft for Enhanced Dura Mater Regeneration

用于增强硬脑膜再生的直径图案硬脑膜移植物

• 批准号: 8735199
• 负责人: Shyam Patel
• 金额: $ 51.22万
• 依托单位: NANONERVE, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-16 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8735199
• 关键词: Achievement; Biodegradation; Biological; Canis familiaris; Cells; Chronic; Clinical; Clinical Trials; Collagen; Defect; Development; Devices; Disadvantaged; Disease; Dura Mater; Ensure; Ethylene Oxide; Excision; Extravasation; Fiber; Goals; Human; Infection; Legal patent; Life; Liquid substance; Malignant Neoplasms; Marketing; Mechanics; Medical Device; Membrane; Meningeal; Modeling; Natural regeneration; Nervous System Trauma; Neuraxis; Neurosurgeon; Neurosurgical Procedures; Operative Surgical Procedures; Oryctolagus cuniculus; Pattern; Performance; Phase; Process; Production; Property; Resistance; Risk; Safety; Solutions; Solvents; Sterility; Sterilization; Surgical sutures; System; Technology; Tensile Strength; Testing; Tissues; Trauma; Validation; base; biomaterial compatibility; clinical efficacy; clinically relevant; commercialization; cost; design; disease transmission; implantation; improved; in vivo; meetings; nanofiber; novel; phase 2 study; pre-clinical; prevent; public health relevance; relating to nervous system; repaired; research and development; research clinical testing; safety testing; scaffold; tissue regeneration

DESCRIPTION (provided by applicant): NanoNerve is developing a novel diametrically patterned nanofibrous dural substitute for rapid dura mater regeneration following neurosurgical procedures. In the US alone, 225,000 neurosurgical procedures are performed annually that require patching of the dura mater to prevent leakage, infection and neural damage. Currently available dural substitutes include xenogenic collagen matrices and permanent synthetic devices. Xenogeneic collagen matrices have significant disadvantages including low mechanical strength, low suturability, and high cost and disease transmission risks. The permanent synthetic devices also suffer from major disadvantages including resistance to dura mater regeneration, need for extensive suturing during implantation and higher leakage rates. The overall goal of the project is FDA 510(K) clearance and commercialization of a highly versatile diametrically patterned nanofibrous dural substitute. NanoNerve is utilizing its patent pending electrospinning technology to diametrically pattern nanofibers for rapidly regenerating dural tissue from the entire periphery of the defect toward the center. NanoNerve's synthetic bioresorbable nanofibrous dural substitute's ultra-thin profile and high mechanical strength will enable it to become the first synthetic dural substitute capable of sutured and suture-free implantation. This Phase II project will continue development of the diametrically patterned nanofibrous dural substitute by performing biocompatibility, safety, stability and long-term in viv implantation studies. Upon achievement of Phase II milestones, NanoNerve will file an FDA IDE application for human clinical testing and, eventually, an FDA 510k for market clearance.

描述（由申请人提供）：NanoNerve正在开发一种新型直径图案纳米纤维硬脑膜替代品，用于神经外科手术后的硬脑膜快速再生。仅在美国，每年就有22.5万例神经外科手术需要修补硬脑膜，以防止渗漏、感染和神经损伤。目前可用的硬脑膜替代品包括异种胶原基质和永久性合成装置。异种胶原基质具有机械强度低、可缝合性低、成本高、疾病传播风险大等显著缺点。永久性合成装置也有主要缺点，包括硬脑膜再生困难，植入过程中需要广泛缝合和较高的泄漏率。该项目的总体目标是FDA 510(K)批准和高度通用的直径图案纳米纤维硬脑膜替代品的商业化。NanoNerve正在利用其正在申请专利的静电纺丝技术，以直径图案纳米纤维快速再生硬脑膜组织，从缺陷的整个外围到中心。NanoNerve的合成生物可吸收纳米纤维硬脑膜替代物的超薄外形和高机械强度将使其成为第一种能够缝合和无缝合植入的合成硬脑膜替代物。该二期项目将通过进行生物相容性、安全性、稳定性和长期体内植入研究，继续开发直径图案纳米纤维硬脑膜替代品。在完成II期里程碑后，NanoNerve将向FDA提交IDE申请进行人体临床试验，并最终向FDA提交510k申请以获得市场许可。